92 related articles for article (PubMed ID: 18609436)
1. Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines.
Menchetti M; Gozzi BF; Saracino MA; Mercolini L; Petio C; Raggi MA
World J Biol Psychiatry; 2009; 10(4 Pt 2):385-9. PubMed ID: 18609436
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders.
Gupta S; Nihalani N; Masand P
Ann Clin Psychiatry; 2007; 19(2):125-32. PubMed ID: 17612852
[TBL] [Abstract][Full Text] [Related]
4. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
Papakostas GI; Worthington JJ; Iosifescu DV; Kinrys G; Burns AM; Fisher LB; Homberger CH; Mischoulon D; Fava M
Depress Anxiety; 2006; 23(3):178-81. PubMed ID: 16528701
[TBL] [Abstract][Full Text] [Related]
5. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
[TBL] [Abstract][Full Text] [Related]
6. Fatal combination of moclobemide overdose and whisky.
Bleumink GS; van Vliet AC; van der Tholen A; Stricker BH
Neth J Med; 2003 Mar; 61(3):88-90. PubMed ID: 12765230
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine treatment of major depressive episodes in the course of psychotic disorders.
Zink M; Knopf U; Mase E; Kuwilsky A; Deuschle M
Pharmacopsychiatry; 2006 May; 39(3):109-11. PubMed ID: 16721699
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
11. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
Müller N; Schennach R; Riedel M; Möller HJ
Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
[TBL] [Abstract][Full Text] [Related]
14. Shock-like sensations associated with duloxetine discontinuation.
Pitchot W; Ansseau M
Ann Clin Psychiatry; 2008; 20(3):175. PubMed ID: 18633745
[No Abstract] [Full Text] [Related]
15. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.
Perahia DG; Quail D; Gandhi P; Walker DJ; Peveler RC
J Affect Disord; 2008 May; 108(1-2):33-41. PubMed ID: 17905442
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
[TBL] [Abstract][Full Text] [Related]
17. Practical psychopharmacologic considerations in depression.
Brasfield KH
Nurs Clin North Am; 1991 Sep; 26(3):651-63. PubMed ID: 1891399
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey.
Waldschmitt C; Vogel F; Pfuhlmann B; Hiemke C
Pharmacopsychiatry; 2009 Sep; 42(5):189-93. PubMed ID: 19724981
[TBL] [Abstract][Full Text] [Related]
20. HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid-phase extraction procedure.
Mercolini L; Mandrioli R; Cazzolla R; Amore M; Raggi MA
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):81-7. PubMed ID: 17572161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
